Our latest articles
Spotlight – Vertex flexes its dealmaking muscle
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.
Lazertinib and Tagrisso go head to head
A key test of J&J’s targeted agent approaches, but Astra has a trick up its sleeve that could render this readout irrelevant.
89Bio Enlivened by Nash success
The company follows Madrigal and Akero with a clinical hit.
Obesity dropouts hurt Altimmune
The company’s value is cut in half as mid-stage data prove a let-down.
AACR 2023 – Moderna's immunotherapeutic splash
This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.
AAD 2023 – Takeda outdoes Bristol’s Sotyktu
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.
Daiichi torches Esperion’s Nexletol milestone promises
Despite assurances by Esperion, Daiichi is refusing to pay up after the Clear Outcomes disappointment.
World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
Europe rues SVB loss as a cornerstone life science supporter
With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?